In this issue of JAMA, Männik and colleagues 1 report that large (>250 kilobase [kb] pairs) structural variants in the genome, specifically deletion and duplication copy number variations (CNVs), were associated with cognitive phenotypes including intellectual disability and reduced educational achievement. These CNVs are deletions and duplications of DNA sequences in the human genome that can be considered as deviations from the normal diploid state at a given location in the genome and represent differing numbers of copies of genetic sequences. The authors also identified and examined the phenotypic consequences of genomic structural variation associated with known genomic disorders 2 among individuals in whom the genomic disorders were not initially clinically recognized.Männik et al initially studied a large Estonian general population, using a random sample cohort of approximately 8000 from the 52 000 DNA samples available in the wellestablished Estonian Genome Center biobank that contains 5% of the adult Estonian population. Importantly, the study participants who were enrolled in the biobank had phenotype information available for study. They were each examined by a general practitioner who completed health-and lifestyle-related questionnaires, and reported clinical diagnoses. Public educational history also was available for analyses.The investigators used genome-wide assays to identify CNVs to determine the medical burden of rare CNVs in the general population. Such genomic assays have been clinically available in Europe and the United States for a decade, often replacing chromosomal analysis, particularly in children manifesting developmental delay. 3 Clinical cytogenetic chromosome studies can identify changes in chromosome number (eg, trisomy 21 associated with Down syndrome) and even some chromosomal microdeletions and microduplications greater than 5 to 10 million base (Mb) pairs in size. However, the new genomic assays used in this study can detect submicroscopic genomic changes including CNVs. Thus, many more genomic changes of potential medical relevance can now be robustly identified using these genome-wide assays.